c-Met inhibitor approved in China for lung cancer

Non-small cell lung cancer

The Chinese National Medical Products Administration (NMPA) has granted conditional approval to Apollomics’ partner Avistone Biotechnology to commercialise vebreltinib (APL-101) in China for MET exon 14 skipping non-small cell lung cancer (NSCLC).

“The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. Apollomics extends its full support and congratulations to Avistone on this significant achievement,” said Guo-Liang Yu, Chairman and Chief Executive Officer of Apollomics.

Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met inhibitor. It works by inhibiting the aberrant activation of the HGF/c-Met axis, a key pathway involved in tumour growth, proliferation, and the development of resistance to certain targeted therapies.

Patients with MET exon 14 skipping mutations comprise approximately 3-4% of all NSCLC cases, and face significant challenges due to limited treatment options.

The SPARTA clinical trial

Apollomics is conducting a multi-cohort Phase II study of vebreltinib, SPARTA, at over 90 centres in 13 countries investigating the efficacy and safety of vebreltinib in MET exon 14 skipping non-small cell lung cancer (NSCLC).

Apollomics is in active discussion with the US Food and Drug Administration (FDA) regarding a New Drug Application (NDA) for vebreltinib based on clinical data from the SPARTA trial and Avistone’s KUNPENG trial in China.

Under the partnership agreement, Avistone holds the exclusive rights to vebreltinib in China, Hong Kong and Macau, while Apollomics retains the exclusive rights in the rest of the world, including the US, and partners have access to each other’s data.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free